Aquestive starts Anaphylm NDA filing; Q4 net loss $17.1M; 2025 revenue guidance $47-56M

Aquestive Therapeutics, Inc.

Q4 2024 total revenues $11.9M, down 10% YoY; full-year revenues $57.6M, up 14%.
Q4 net loss $17.1M ($0.19/sh) vs $8.1M loss ($0.12/sh) YoY; FY net loss $44.1M ($0.51/sh) vs $7.9M ($0.13/sh).
Anaphylm NDA submission started, FDA acceptance expected Q2 2025; launch targeted Q1 2026 if approved.
AQST-108 Phase 2a in alopecia areata to begin Q2 2025; Libervant court ruling appealed, product remains on market.
Pro-forma cash ~$93M including $21.4M ATM proceeds in Feb 2025; 2025 revenue guidance $47-56M, Non-GAAP EBITDA loss $46-53M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.